key: cord-0874703-cctjuqfj
authors: Hafkamp, Frederique J.; Tio, Rene A.; Otterspoor, Luuk C.; de Greef, Tineke; van Steenbergen, Gijs J.; van de Ven, Arjen R. T.; Smits, Geert; Post, Hans; van Veghel, Dennis
title: Optimal effectiveness of heart failure management — an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure
date: 2022-03-03
journal: Heart Fail Rev
DOI: 10.1007/s10741-021-10212-8
sha: f9ca86bf838a6b220782ed996d201c1f50746b41
doc_id: 874703
cord_uid: cctjuqfj

Heart failure (HF) is a major health concern, which accounts for 1–2% of all hospital admissions. Nevertheless, there remains a knowledge gap concerning which interventions contribute to effective prevention of HF (re)hospitalization. Therefore, this umbrella review aims to systematically review meta-analyses that examined the effectiveness of interventions in reducing HF-related (re)hospitalization in HFrEF patients. An electronic literature search was performed in PubMed, Web of Science, PsycInfo, Cochrane Reviews, CINAHL, and Medline to identify eligible studies published in the English language in the past 10 years. Primarily, to synthesize the meta-analyzed data, a best-evidence synthesis was used in which meta-analyses were classified based on level of validity. Secondarily, all unique RCTS were extracted from the meta-analyses and examined. A total of 44 meta-analyses were included which encompassed 186 unique RCTs. Strong or moderate evidence suggested that catheter ablation, cardiac resynchronization therapy, cardiac rehabilitation, telemonitoring, and RAAS inhibitors could reduce (re)hospitalization. Additionally, limited evidence suggested that multidisciplinary clinic or self-management promotion programs, beta-blockers, statins, and mitral valve therapy could reduce HF hospitalization. No, or conflicting evidence was found for the effects of cell therapy or anticoagulation. This umbrella review highlights different levels of evidence regarding the effectiveness of several interventions in reducing HF-related (re)hospitalization in HFrEF patients. It could guide future guideline development in optimizing care pathways for heart failure patients.

Heart failure (HF) is a major health concern, with mortality ranging from 5 to 40% [1] , corresponding with a fivefold increased risk of death, compared to the general population [2] . It is even estimated that HF patients have a worse life expectancy than the majority of cancer patients, with a median survival of approximately 2 to 3 years [3, 4] . More than 400,000 patients in the USA are being diagnosed with HF, annually [5] . Moreover, prevalence rates are progressively rising and are expected to increase with 46% from 2012 to 2030 [6, 7] .

In addition, heart failure is the diagnosis with the highest readmission rates among all diseases [8] [9] [10] [11] , as it accounts for 1 to 2% of all hospital admissions [12, 13] . In elderly people, it is the major cause of hospitalization [8] . Most patients are hospitalized at least once a year after diagnosis (i.e., 68 to 78% of patients) [8, 14, 15] , and more than one-fourth is at risk of being readmitted within 30 days after initial diagnosis [8, [15] [16] [17] [18] . Comparatively to prevalence rates, the total number of hospitalizations is also expected to rise, by 50% in the near future [19, 20] .

Hospitalization places a great burden on patients [21] . Patients may experience various limitations in their activities of daily living [22] [23] [24] , which highly impact their quality of life and level of satisfaction [21, 25] . Moreover, aside from a reduced quality of life, patients who are hospitalized have a significantly higher risk of death than non-hospitalized patients [26, 27] . Additionally, hospitalization due to HF places a great burden on the healthcare system, as it accounts for more than half of total healthcare costs [28, 29] corresponding with more than > 15 billion dollars a year for the American healthcare system [24, 30, 31] . HF is the most costly condition in western countries and since long time hospitalization for HF even exceeds the hospitalization costs for both cancer and myocardial infarction combined [32, 33] . Accordingly, hospitalization is judged as a highly important outcome measure in (inter) national literature and registries [34, 35] .

Nevertheless, despite the rising prevalence rates, it seems that up to 40% of hospitalizations could be classified as preventable [36] [37] [38] [39] [40] . Therefore, the reduction of hospitalizations is the most promising factor as target to improve patients' reported experiences or outcomes and to reduce the costs of HF management [25, 41, 42] . The combined measure of patient outcomes and costs are the main goal in value based healthcare, a well-known and promising strategy in healthcare in order to improve patient value [43] [44] [45] .

Multiple previous studies examined the effect of various interventions to reduce (re)hospitalization in HF, mostly in patients with an left ventricular ejection fraction (LVEF) < 40% (i.e., patients with HFrEF) [46] , but contrasting findings are found within the literature regarding the effectiveness of these interventions in reducing hospital admissions [47, 48] . Moreover, there is some considerable heterogeneity in strategies and methods used in previous studies [49] . Some studies, for example, focused on remote monitoring to prevent readmissions, while others examined quality improvement of interventions or transitional care systems [36, 37, [50] [51] [52] . Therefore, there remains a gap in information concerning which interventions could effectively contribute to effective prevention of HF hospitalization or readmission [47, 48, 53, 54] .

Hence, even though multiple interventions have been included in the guidelines for treatment of HF [46, 55] , there is a compelling need of a comprehensive overview of which types of interventions prove effective specifically in reducing HF hospitalizations, especially in HFrEF patients. This umbrella review therefore aims to systematically review all published meta-analyses conducted in the past 10 years that examined the incremental effect of different interventions in addition to standard care, to reduce (re)hospitalization in HFrEF patients, in order to highlight different levels of evidence regarding their effectiveness.

The systematic review protocol of this review was registered, in accordance with the PRISMA guidelines, at the International Prospective Register of Systematic Reviews (PROS-PERO) on July 6, 2020 (registration number: 247872).

An electronic literature search was performed in PubMed, Web of Science, PsycInfo, Cochrane Reviews, CINAHL, and Medline to identify eligible studies published in the English language from January 2010 up to the end of June 2020. Search terms were developed using MeSH terms. Key words were related to (1) interventions, (2) heart failure, (3) hospitalization, and (4) meta-analysis (Table 1) .

Ample differences existed in the classification of categories of interventions depicted in the existing literature. For example, previous reviews classified interventions in either educational interventions, pharmacological interventions, telemonitoring (TM), structured telephone support (STS), nurse home visits, nurse care management, and disease management clinics [41] ; or discharge planning protocols, comprehensive geriatric assessments, discharge support arrangements, and educational interventions [56] ; or case management interventions, clinical interventions, and multidisciplinary interventions [53] ; or predischarge interventions, postdischarge interventions, and interventions bridging the transition [57] . A list of 4 categories of interventions was derived following a scoping review that combine the most common interventions aimed at reducing hospital (re) admissions, cardiac rehabilitation, care pathways, medication, and invasive treatment. Both general terms linked to the concept of interventions (e.g., programs, inventions, therapy) and terms for specific examples of (categories of) interventions were included in the search strategy. : TS = (meta analysis OR meta-analysis OR meta analy* OR metaanaly* OR meta-analy*) #3: TS = (hospitalization* OR rehospitalization* OR admission* OR re-admission* OR readmission* OR length of stay) #4: TS = (*Heart failure OR cardiac failure OR congestive* OR left ventricular dysfunction OR CHF) #5: #4 AND #3 AND #2 AND #1 

Search results of all databases were combined, and duplicates were removed. Titles and abstracts were screened against the following inclusion criteria: (1) a meta-analysis was conducted, on (2) randomized controlled trials (RCTs), (3) that examined the effectiveness of (3.a) cardiac rehabilitation, or (3.b) care pathways, or (3.c) medication, or (3.d) invasive therapy, (4) in patients with an established diagnosis of chronic heart failure, (5) with an LVEF < 40, (6) with a primary or secondary objective to evaluate the effect on reduction of (7) HF-related hospitalization or readmissions, (8) as compared to usual care, (9) conducted in the past 10 years, (10) followed patients for at least three months, and (11) were reported in English. Meta-analyses that included both RCTs and observational or cohort studies were not excluded. Yet only the included RCTs (and corresponding meta-analyzed effect sized) were extracted and used for our analyses. Only meta-analyses that reported at least one meta-analyzed effect estimate for HF-related admissions were included. In order to assure objective assessment, the title and abstract screening were independently conducted by two researchers (FH, TG). In case of disagreement between reviewers, points of disagreement were discussed in order to reach consensus. For full-text screening, inter-rate reliability was calculated using Cohen's kappa. Studies were excluded when the patient population was not primarily diagnosed with heart failure (e.g., patients with diabetes and comorbid heart failure). Additionally, if studies examined HF patients in combination with other patient groups yet did not report data on the individual patient groups, the study was excluded, as we would otherwise be unable to make a distinction between the differences in patient groups. Furthermore, studies that only reported data on a combined endpoint (e.g., mortality in conjunction with HF-hospitalization) and meta-analyses that examined risk stratification, prognostic factors, or lifestyle advice in patients were excluded. Moreover, meta-analyses were also excluded when examining a specific subgroup of HF patients (e.g., patients with and LVAD) or when examining a broader category of patients that could possibly include HF patients (e.g., "older patients" in general).

The "A MeaSurement Tool to Assess systematic Reviews 2" (AMSTAR 2) was used to assess the methodological quality of included meta-analyses [58] . AMSTAR 2 consists of 16 items, of which 10 items were retained from the original AMSTAR tool. Response options for the items were "yes," "partial yes," and "no," with "yes" responses denoting a positive result. The overall score of this tool was converted to high quality, moderate quality, low quality, and critically low quality. High quality was achieved when studies possessed no or one non-critical weakness; moderate quality was achieved when studies had more than one non-critical weakness; low quality was achieved when studies had one critical flaw, with or without a non-critical weakness; and critically low quality was achieved when studies exhibited more than one critical flaw with or without non-critical weaknesses. Critical domains are depicted in Table 2 [58] . In order to assure objective assessment, the quality assessment was independently conducted by two researchers (GS, TG). In case of disagreement between reviewers, points of disagreement were discussed in order to reach consensus (RT).

A standardized extraction form was used to extract data from the included studies. Sociodemographic data (e.g., age, sex), number of participants, left ventricular ejection fraction, type of intervention and control, follow-up period, effect size, and conclusion were extracted from either the individual RCT or the meta-analysis in which the RCT was included. Only the most recent meta-analysis was included when multiple articles were written by the same authors on the same dataset. Comparisons were made between the different categories of interventions in terms of effectiveness in reducing HF-related (re)hospitalization. Interventions were classified as having a significant effect on HF-related (re) hospitalization (as compared to usual care) based on their own reported RR statistics, findings, and conclusions.

Interventions were first classified into the four predefined categories (i.e., cardiac rehabilitation, care pathways, medication, and invasive therapy) and subsequently divided into more detailed classes of interventions (e.g., TM and STS) to examine the exact effect of all unique interventions.

To synthesize the data, a best-evidence synthesis was used as primary analysis, in which meta-analyses were classified based on level of internal and external validity [59] . The levels of evidence regarding the significance or non-significance of a relationship between the intervention and HF-related hospitalization among studies were ranked according to the following statements: (1) strong evidence: consistent findings (> 75% of the studies reported consistent findings) in multiple high quality studies; (2) moderate evidence: consistent findings (> 75% of the studies reported consistent findings) in one high-quality study and two or more moderate quality studies or in three or more weak quality studies; (3) limited evidence: generally consistent findings (> 75% of the studies reported consistent findings) in a high quality study or in two or fewer moderate quality studies; (4) no evidence: no studies could be found; (5) conflicting evidence: conflicting findings.

It was expected that multiple meta-analyses would report identical RCTs, as it was previously found that the amount of redundancy and duplication among reviews is substantial [60, 61] . Therefore, the corrected covered area (CCA) was calculated, which is a measure of duplicates in meta-analyses divided by the frequency of duplicates, reduced by the number of original publications (Corrected covered area = N−r r c−r ) [62] . A CCA of 0-5% is considered as slight overlap, while 6-10%, 11-15%, > 15% are respectively regarded as moderate, high, and very high overlap. In order to prevent bias as a result of duplicated data, a secondary analysis was conducted to control for the effects of overlap. All unique RCTs were extracted from the meta-analyses. Individual risk ratios (RRs) and 95% CIs for each intervention were calculated using Review Manager V.5.4. or extracted from the meta-analyses. The I 2 -statistic was used to present the heterogeneity of intervention effect. When the I 2 -statistic was statistically significant, a random-effects model was used in analyses. The RR-statistics found in our own metaanalyses were compared to the reported effects in the published meta-analyses.

After removal of duplicate meta-analyses, 639 titles and abstracts were screened (see Fig. 1 ). A total of 202 full-text articles were assessed for eligibility, of which 44 were included in our analyses. Cohen's kappa for full-text screening was 0.76, indicating substantial agreement [63] . Median year of publication of all included meta-analyses was 2018. The 44 included meta-analyses encompassed 348 RCTs of which 186 were unique RCTs regarding interventions to prevent HF hospitalization (Table 3) . Of these 186 unique RCTs, 44 were classified as invasive therapy, 14 as cardiac rehabilitation, 60 as medication, and 67 as care pathways ( Table 4 ). The CCA for cardiac revalidation was 

Overall, risk of bias was classified as relatively low (Table 5 ). Of the 44 meta-analyses, 11 scored critically low, 15 low, 1 moderate, and 17 high. Almost all meta-analyses registered their protocol before commencement of the review (item 2) and used appropriate meta-analytical methods (item 11). Reviews were mostly downgraded based on the lack of an adequate investigation of publication bias (item 15).

A total of 425,220 patients were included in the 44 metaanalyses and 186 RCTs (Table 4 ). RCTs included between 16 and 10,917 patients. The mean age of patients ranged from 33 to 96 years. Mean LVEF varied between 17 and 40%. Percentage of male patients ranged from 25 to 100%. Follow-up period ranged widely from 30 days to 10 years. Studies that tried to prevent hospital admissions with cardiac rehabilitation focused on either exercise only or multicomponent cardiac rehabilitation. Care pathways could be divided into either TM, STS, and self-management promotion programs or multidisciplinary clinics. Invasive therapy encompassed catheter ablation (CA), cardiac resynchronization therapy (CRT), mitral valve repair, or stem cell therapy. Medication subtypes were angiotensinconverting enzyme inhibitors (ACE), angiotensin II receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), beta-blockers, statins, anticoagulation, and a miscellaneous subcategory. Maggioni et al. [190] 2002

Margulies et al. [191] 2016

Marrouche et al. [192] 2018 x x Martinelli et al. [193] 2010

x Mathiasen et al. [194] 2015

x Menasché [195] 2008

x

Mcdonald et al. [196] 2002

McMurray et al. [197] Maggioni et al. [190] 2002

x Margulies et al. [191] 2016

x Marrouche et al. [192] 2018

x x x

x Martinelli et al. [193] 2010

Mathiasen et al. [194] 2015

Menasché [195] 2008

Mcdonald et al. [196] 2002

x

McMurray et al. [197] 

Meta-analytic results of the 44 included meta-analyses are demonstrated in Table 6 and Fig. 2 . According to our bestevidence synthesis, strong evidence suggests that CA, CR, and TM could prevent heart failure hospitalization. Furthermore, moderate evidence was found for the effectiveness of RAAS inhibitors, and CRT in reducing HF-related hospitalizations, while only limited evidence suggests the beneficial effects of beta-blockers, statins, mitral valve therapy, and multidisciplinary clinics or self-management promotion programs. There is conflicting evidence regarding the effect of cell therapy on HF hospitalization, and no evidence was found that anticoagulation should reduce HFrelated hospitalizations.

In order to prevent bias as a result of duplicated data, all unique RCTs (N = 186) were extracted in a secondary analysis from the meta-analyses and compared to the results from our primary analysis.

A total of 14 studies examined the effects of cardiac rehabilitation. Of these individual studies, 1 reported a significant effect. When examined in a meta-analysis, a significant positive effect of cardiac rehabilitation was found (RR: 0.66, 95% CI: 0.44 | 0.97) (Fig. 3 ). This is in accordance with the general findings reported by the studied meta-analyses. Upon visual inspection, the funnel plots suggest no publication bias (Fig. 7) .

There were 5 studies examining the effect of CA. Of these studies, 2 studies reported a significant effect. A positive effect of CA on HF-related hospitalization was found in our meta-analyses (RR: 0.57, 95% CI: 0.46 | 0.72) (Fig. 4) . This is consistent with the general findings reported by the studied meta-analyses.

A total of 23 studies examined CRT to prevent HF-related hospitalization. Of these, 8 studies found a positive effect. Our meta-analysis suggested a positive effect of CRT (RR: 0.85, 95% CI: 0.78 | 0.92). This is in line with the general findings reported by the studied meta-analyses.

Of the 4 studies that examined mitral valve repair, 3 reported an effective reduction in HF-related hospitalization. Our meta-analyses suggested a positive effect (RR: 0.74, The patients enrolled in HT strategies 2 and 3 transmitted weekly records of the following data to the coordinating center via an automated interactive voice response system: weight; heart rate; systolic arterial pressure; dyspnea score; asthenia score; oedema score; changes in therapy; and blood results

Patients allocated to the control arm were discharged as normal from the hospital Home-based disease management program to monitor and to detect early signs and symptoms of heart failure using telecommunication equipment Patient 1-on-1 education, an effort to use evidencedbased optimal medical treatment, and a commercially available digital home scale with management by primary physician Specialized primary and networked care in heart failure disease management program Disease management program in conjunction with the AHM system 95% CI: 0.64 | 0.86), which is in agreement with the general findings reported by the studied meta-analyses. Stem cell therapy was in 0 of the 13 studies related to reduced HF-related hospitalization, which is in line with our meta-analyzed result (RR: 0.71, 95% CI: 0.45 | 1.14) and the conflicting evidence suggested by the studied meta-analyses.

The funnel plots indicate no, or only minimal publication bias (Fig. 7) . 5 ). This is in line with the general findings reported by the studied meta-analyses.

Anticoagulation (RR: 0.99, 95% CI: 0.91 | 1.08) was in none of the studies (0/3) able to reduce HF-related hospitalizations. This absence of an effect was also reported by the studied meta-analyses.

The asymmetry in the medication funnel plots suggests some publication bias towards significant effectiveness of medication in reducing HF-related hospitalizations (Fig. 7) .

Multidisciplinary clinics or self-management promotion programs (10/23 studies; RR: 0.79, 95% CI: 0.73 | 0.85) and TM (12/33 studies; RR: 0.86, 95% CI: 0.81 | 0.92) were related to less HF-related hospitalizations (Fig. 6 ). This is in agreement with findings reported by the studied metaanalyses. STS (1/11 studies; RR: 0.85, 95% CI: 0.85 | 1.04) was not related to reductions in HF-related hospitalizations. This is in contrast to findings from the meta-analyses. Visual inspection of the funnel plots did not suggest publication bias (Fig. 7 ).

Heart failure is a major health concern, with the highest readmission rates among all diseases [8] [9] [10] [11] . Yet, up to 40% of hospitalizations could be classified as preventable [36] [37] [38] [39] [40] . This umbrella review therefore aimed to systematically review all published meta-analyses conducted in the past 10 years that examined the incremental benefit of interventions in addition to standard care, in reducing HFrelated (re)hospitalization, in order to provide a comprehensive overview of different levels of evidence with regard to . 3 Forest plot of RR for HF-related hospitalization between cardiac rehabilitation and control. Random effects model medication, and care pathways) entail interventions that prove able to statistically significantly reduce HF-related hospitalizations. Strong or at least moderate evidence was found for the beneficial effects of CA, CRT, ACE inhibitors, MRAs, ARBs, CR, TM, and STS. Limited evidence was found for the ability of beta-blockers,, statins, mitral valve repair, and multidisciplinary clinics or self-management promotion programs to reduce hospitalization rates. Conflicting or no evidence was found for the effects of anticoagulation and stem cell therapy. The findings of this umbrella review were generally supported by the American Heart Association and European Society of Cardiology heart failure guidelines [46, 64] . Yet, evidence for effectiveness was still lacking for several interventions in these guidelines. A couple of interventions proposed in the guidelines had low levels of evidence, as they were only supported by a single randomized clinical trial. Although these guidelines do not solely focus on the prevention of (re)hospitalization, this umbrella review now provides additional evidence for the effectiveness of ARBs (e.g., Valsartan) and telemonitoring as effective in the prevention of (re)hospitalization in heart failure. Therefore, the results of this review may be used in addition in clinical practice, as well as by policymakers, as a guideline in deciding what treatment option might help prevent hospitalization in at risk heart failure patients.

Effectiveness of reported interventions was measured in terms of a reduced risk for heart failure related Non-effectiveness of treatment could also be related to non-adherence or non-acceptance of the intervention by the patient, since it is estimated that non-adherence ranges between 30 and 50% in patients with chronic illnesses [65] . And non-adherence not only holds for medication, yet also for cardiac rehabilitation [66, 67] and telemonitoring [68, 69] . It has been shown that worsening of HF is often related to non-adherence of patients [70] and is in fact associated with 10% of hospitalizations [65, 71] and a 10% increased risk of readmission [72] . The other way around, reductions in non-adherence are found to result in less hospital admissions [73] .

Differences in non-adherence to different forms of interventions were also found. For example, patients are found to be more adherent to ACE-inhibitors (77.8%) as compared to beta-blockers (69.8%) [74] . These differences could be explained by cognitions of patients regarding the efficacy of the intervention and the usability of the intervention [75] . Moreover, low health literacy or simply a lack of knowledge about the syndrome could also contribute to non-adherence [76] [77] [78] . In clinical practice, one should therefore educate patients about the importance of disease management with medication, invasive therapy, cardiac rehabilitation, and care pathways [65, 79] .

Moreover, when implementing interventions in practice, one should not only focus on effectiveness, yet also incorporate, for example, the costs of the intervention. Especially, since HF is the most costly condition in western countries, with at least twice the costs of the estimated consumption of healthcare in the general population in a year [32, 33, 80], mainly due to HF-related hospitalization [28, 29] . Research has shown that, in terms of cost-effectiveness, medication treatment with beta-blockers, ARBs, or ACE inhibitors could be preferred over more cost expensive therapies as device therapy with CRT [81, 82] . More specifically, with regard to specific forms of medication, ivabradine seems a cost-effective treatment option, while this does not hold for valsartan [82] . In addition, general HF treatment combined with telemonitoring has been found to be between 27 and 52% more cost-efficient than usual care alone [83, 84] . Furthermore, telemonitoring seems not only cost-efficient; but nowadays, with the pandemic consequences of COVID-19 c d Fig. 4 (continued) it seems more desired than ever [85] . The pandemic served as a catalyst, as both healthcare professionals as patients wanted optimal care in a time of reduced ambulatory outpatient clinics, with being compliant to social distancing [84] . Our review shows, in addition, that, even though the terms are interchangeably used to both describe some form of "remote care," telemonitoring and structured telephone support have different levels of effectiveness with regard to prevention of heart failure related (re)hospitalizations, which should be accounted for in clinical practice.

In this umbrella review, we only aimed to provide an overview of effective treatment options for prevention of heart failure (re)hospitalization. Consequently, no conclusions could be drawn regarding the hierarchy of effectiveness based upon this review. In future research, it should be examined what factors contribute to effectiveness of interventions, as our study only showed that particular interventions could reduce heart failure hospitalizations, but not why per se. Research should focus on the effective mechanisms of care pathway programs, for example, or on determinants of successful implementations of interventions for heart failure.

The aim of our review was to assess interventions which are currently used in clinical practice and examined in large populations. Our results are based upon metaanalyses performed within the past 10 years. Yet, most For example, no study examined the effects of SGLT-II inhibitors, while the European Society of Cardiology stated that SGLT-II inhibitors could be preferred in heart failure patients [86] . Future studies should examine whether the use of SGLT-II inhibitors could show effective in reducing hospitalization. Moreover, as the aim of our review was to assess interventions which are currently used in clinical practice and examined in large populations, we expected to find multiple meta-analyses examining the same interventions. A large amount of overlap in RCTs in included meta-analyses was found. This stresses the importance of registration of protocols and knowing whether the intended research subject has a significantly different research objective than existing, or outdated reviews [62] . To conclude, this umbrella review highlights different levels of evidence regarding the effectiveness of several interventions in reducing HF-related hospitalization in HFrEF patients. It provides an overview of all, known, meta-analyses conducted in the past 10 years that examined interventions to prevent heart failure related hospitalizations. All different categories of interventions entail interventions that prove able to statistically significantly reduce HF-related hospitalizations. Most evidence was found for the beneficial effects of angiotensin-converting enzyme inhibitors (ACE), mineralocorticoid receptor antagonists (MRAs), angiotensin II receptor blockers (ARBs), cardiac rehabilitation, and telemonitoring. The results of this review may be used in clinical practice, as well as by policymakers, to guide treatment for heart failure patients at risk of hospitalization. Author contribution All authors made substantial contributions to conception and design, and/or acquisition of data, and/or analysis and interpretation of data. All authors participated in drafting the article or revising it critically for important intellectual content gave final approval of the version to be submitted and any revised version.

Ethical approval The study has been performed in accordance with the ethical standards in the 1964 Declaration of Helsinki and with relevant regulations of the US Health Insurance Portability and Accountability Act (HIPAA).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. 

Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management

Sex-specific epidemiology of heart failure risk and mortality in Europe: results from the BiomarCaRE consortium

Do patients have worse outcomes in heart failure than in cancer? a primary care-based cohort study with 10-year follow-up in Scotland

The epidemiology of heart failure: the Framingham study

Heart and stroke statistical update

Clinical epidemiology of heart failure

Forecasting the impact of heart failure in the United States: a policy statement from the american heart association

Rehospitalizations among patients in the medicare fee-for-service program

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the medicare population

Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia

Readmissions among patients admitted with acute decompensated heart failure based on income quartiles

Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating study evaluating outcomes of advising and counseling in heart failure (COACH)

Impact of home versus clinic-based management of chronic heart failure: the WHICH? (which heart failure intervention is most costeffective & consumer friendly in reducing hospital care) multicenter, randomized trial

Contemporary evidence about hospital strategies for reducing 30-day readmissions: a national study

Identifying quality improvement intervention evaluations: is consensus achievable?

Effects of home telemonitoring interventions on patients with chronic heart failure: an overview of systematic reviews

The importance of transitional care in achieving health reform

Clinical service organisation for heart failure

Which Heart failure Intervention is most Cost-effective and consumer friendly in reducing Hospital care (WHICH?): a multicentre randomised controlled trial

ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison

A systematic review of discharge arrangements for older people. Database of abstracts of reviews of effects (DARE): Qualityassessed reviews

Interventions to reduce 30-day rehospitalization: a systematic review

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

Best evidence synthesis: an intelligent alternative to meta-analysis

Overview of systematic reviews of non-vitamin K oral anticoagulants in atrial fibrillation: evidence of publication overlap

Replication, duplication, and waste in a quarter million systematic reviews and meta-analyses

Systematic review finds overlapping reviews were not mentioned in every other overview

Interrater reliability: the kappa statistic

ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/ american heart association task force on practice guidelines

Interventions to improve medication adherence: a review

Cardiac rehabilitation uptake and its determinants in the Netherlands

Cardiac rehabilitation enrollment among referred patients: patient and organizational factors

Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial

Telemonitoring in patients with heart failure

Compliance in heart failure patients: the importance of knowledge and beliefs

Investigators Q (2017) Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

Medication adherence as a predictor of 30-day hospital readmissions

Association between medication adherence and the outcomes of heart failure

Medication adherence to specific drug classes in chronic heart failure

Patient adherence to a mobile phone-based heart failure telemonitoring program: a longitudinal mixed-methods study

A story of maladies, misconceptions and mishaps: effective management of heart failure

Understanding adherence to the CardioMEMS pulmonary artery pressure monitoring system for heart failure: a qualitative study

A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence

Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials

Long term health care consumption and cost expenditure in systolic heart failure

Cost-effectiveness of heart failure therapies

Managing the economic challenges in the treatment of heart failure

Identification of cost indicators with significant economic impact on the total treatment costs of chronic heart vailure patients-a metaanalysis

Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic: the advantages of universal access to home telemonitoring

Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the heart failure society of America

Heart failure association of the european society of cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure

Cardiac resynchronization in chronic heart failure

Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure

Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure

Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of the reducing decompensation events utilizing intracardiac pressures in patients With chronic heart failure (REDUCEhf) trial

Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial

Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the interdisciplinary network for heart failure (INH) study

Impact of telemonitoring at home on the management of elderly patients with congestive heart failure

Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients

Regenerative therapy in cardiology: how distant is it from reality

Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial

Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program

Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure

Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease

Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineagespecified biologics

Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome

10-year exercise training in chronic heart failure: a randomized controlled trial

Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group

Economic analysis of a randomized trial of biventricular pacing in Canada

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

Educational home follow-up by telemedicine in cases of cardiac insufficiency. Randomised, multicentric study from the Basse-Normandie region. Preliminary results

The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy

Randomised controlled trial of specialist nurse intervention in heart failure

Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results

Fluid status telemedicine alerts for heart failure: a randomized controlled trial

Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial

Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial

Tailored telemonitoring in patients with heart failure: results of a multicentre randomized controlled trial

Carvedilol produces doserelated improvements in left ventricular function and survival in subjects with chronic heart failure

Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group

Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study

Cost/ utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care

Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay

Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure

Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure

Home-based cardiac rehabilitation improves quality of life, aerobic capacity, and readmission rates in patients with chronic heart failure

Feasibility of biventricular pacing in patients with recent myocardial infarction: impact on ventricular remodeling

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure

Cost effective management programme for heart failure reduces hospitalisation

A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure

Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

Improving care for patients with acute heart failure: before, during and after hospitalization

The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: the REACH-HF multicentre randomized controlled trial

A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home-HF study

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic L

Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study

Multisite randomized trial of a single-session versus multisession literacysensitive self-care intervention for patients with heart failure

Natale A (2016) Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial

The effect of digoxin on mortality and morbidity in patients with heart failure

The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study)

Noninvasive remote telemonitoring for ambulatory patients with heart failure: effect on number of hospitalizations, days in hospital, and quality of life. CARME (CAtalan Remote Management Evaluation) study

Education and telephone monitoring by nurses of patients with heart failure: randomized clinical trial

Randomized, controlled trial of integrated heart failure management: the Auckland Heart Failure Management Study

Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial

Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure

Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure

High-intensity interval training in patients with heart failure with reduced ejection fraction

Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group

Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial

Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure

Heart failure virtual consultation: bridging the gap of heart failure care in the community -a mixed-methods evaluation

Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the bi vs left ventricular pacing: an international pilot evaluation on heart failure

Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study

Comparison of percutaneous mitral valve repair versus conservative treatment in severe functional mitral regurgitation

Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology

Multicenter randomised trial on home-based telemanagement to prevent hospital readmission of patients with chronic heart failure

Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial

XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

Shortterm adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure

Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles

Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial

Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial

Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial

INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients with Remotely Monitored Implanted Cardioverter Defibrillators SysTems (InContact)

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial

Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias

Implant-based multiparameter telemonitoring of patients with heart failure

Home telemedicine in heart failure: a pilot study of integrated telemonitoring and virtual provider appointments

A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: the Birmingham Rehabilitation Uptake Maximisation study for patients with Congestive Heart Failure (BRUM-CHF) study

Catheter ablation versus rate control for atrial fibrillation: what have we learnt from the ARC-HF trial?

Managing heart failure care using an Internet-based telemedicine system

A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission

Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study

Prevalence of anemia in patients with chronic heart failure and their clinical characteristics

The value of telemonitoring and ICT-guided disease management in heart failure: Results from the IN TOUCH study

Telephone support to rural and remote patients with heart failure: the Chronic Heart Failure Assessment by Telephone (CHAT) study

Randomized trial of an education and support intervention to prevent readmission of patients with heart failure

Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study

Case management in a heterogeneous congestive heart failure population: a randomized controlled trial

Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study

Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF Study

Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms

Edema index-guided disease management improves 6-month outcomes of patients with acute heart failure

A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias

Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study

Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial

Catheter ablation for atrial fibrillation with heart failure

Conventional versus biventricular pacing in heart failure and bradyarrhythmia: the COMBAT study

Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)

Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure

Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial

Remote management of heart failure using implantable electronic devices

Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure)

MADIT-II: clinical implications

Cardiacresynchronization therapy for the prevention of heart-failure events

Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot study

Exercise capacity, physical activity patterns and outcomes six years after cardiac rehabilitation in patients with heart failure

Shortterm statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

Percutaneous repair or medical treatment for secondary mitral regurgitation

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

Effect of carvedilol on survival in severe chronic heart failure

Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure

Stem cell therapy for heart failure

Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: a prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass

Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure

Case management for patients with chronic systolic heart failure in primary care: the HICMan exploratory randomised controlled trial

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity

Assessment of resynchronization therapy on functional status and quality of life in patients requiring an implantable defibrillator

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Coronary artery bypass grafting with and without concomitant epicardial cardiac resynchronization therapy in patients with ischemic cardiomyopathy: a randomized study

Cardiac resynchronization therapy and bone marrow cell transplantation in patients with ischemic heart failure and electromechanical dyssynchrony: a randomized pilot study

Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study

Impact of a comprehensive telephone-based disease management programme on quality-of-life in patients with heart failure

Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

Cardiac-resynchronization therapy in heart failure with a narrow QRS complex

Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study

Effect of home-based telemonitoring using mobile phone technology on the outcome of heart failure patients after an episode of acute decompensation: randomized controlled trial

Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar)

Effects of nurse management on the quality of heart failure care in minority communities: a randomized trial

Multidisciplinary group clinic appointments: the Self-Management and Care of Heart Failure (SMAC-HF) trial

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study

Transcatheter mitral-valve repair in patients with heart failure

Effect of β1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study)

Cardiac-resynchronization therapy for mild-to-moderate heart failure

Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study CONSENSUS)

Evaluation of resynchronization therapy for heart failure in patients with a QRS duration greater than 120 ms (GREATER-EARTH) trial: rationale, design, and baseline characteristics

Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial

A multicenter disease management program for hospitalized patients with heart failure

Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy

Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)

Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure

Disease management for heart failure patients: role of wireless technologies for telemedicine. The ICAROS project

Clinical and psychological telemonitoring and telecare of high risk heart failure patients

Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease

Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure

Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure

Use of home telemonitoring to support multidisciplinary care of heart failure patients in Finland: randomized controlled trial

A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: the SPAN-CHF II trial

A new programme of multidisciplinary care for patients with heart failure in Poznań: one-year follow-up

Effects on quality of life, symptoms and daily activity 6 months after termination of an exercise training programme in heart failure patients

Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels

Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure

Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study

Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial

Patient engagement with a mobile web-based selfmanagement: a pilot study

Eplerenone in patients with systolic heart failure and mild symptoms

Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease

Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials

Catheter ablation for treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis

Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure

Remote monitoring of implantable cardiac devices in heart failure patients: a systematic review and meta-analysis of randomized controlled trials

Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and metaanalysis of randomized controlled trials

Percutaneous Mitral Valve Repair Vs. Stand-alone medical therapy in patients with functional mitral regurgitation and heart failure

Prognostic impact of MitraClip in patients with left ventricular dysfunction and functional mitral valve regurgitation: a comprehensive meta-analysis of RCTs and adjusted observational studies

Exercisebased cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): a systematic review and meta-analysis

Lipophilic statin versus rosuvastatin (hydrophilic) treatment for heart failure: a meta-analysis and adjusted indirect comparison of randomised trials

Mobile technologies for managing heart failure: a systematic review and meta-analysis

Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials

Nurse-led titration of angiotensin converting enzyme inhibitors, betaadrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction

Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure

Metaanalysis of cell therapy trials for patients with heart failure

Stem cell therapy for chronic ischaemic heart disease and congestive heart failure

Multidisciplinary heart failure clinics are associated with lower heart failure hospitalization and mortality: systematic review and meta-analysis

Device monitoring in heart failure management: outcomes based on a systematic review and meta-analysis

The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis

Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and metaanalysis

Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Coc

Structured telephone support or non-invasive telemonitoring for patients with heart failure

Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis

What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis

Cardiac resynchronization therapy and QRS duration: systematic review, meta-analysis, and meta-regression

Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure

Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis

Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials

Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials

Comparative therapeutic assessment of atrial fibrillation in heart failure with reduced ejection fraction-a network meta-analysis

The impact of catheter ablation for atrial fibrillation in heart failure

Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis

The effect of reninangiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis

A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis

Exercise-based rehabilitation for heart failure cochrane systematic review, metaanalysis, and trial sequential analysis

Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials

Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines

Telemonitoring and hemodynamic monitoring to reduce hospitalization rates in heart failure: a systematic review and meta-analysis of randomized controlled trials and real-world studies

Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials

Catheter ablation of atrial fibrillation in patients with heart failure a meta-analysis of randomized controlled trials

Effect of postdischarge virtual wards on improving outcomes in heart failure and non-heart failure populations: a systematic review and metaanalysis

Meta-analysis and meta-regression of telehealth programmes for patients with chronic heart failure

Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis

The influence of liraglutide for heart failure: a meta-analysis of randomized controlled trials

Is treatment with trimetazidine beneficial in patients with chronic heart failure?

Cobelli F (2004) Heart failure case disease management program: a pilot study of home telemonitoring versus usual care

Anker SD (2012) Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trial

A randomized clinical trial of the clinical effects of enhanced heart failure monitoring using a computerbased telephonic monitoring system in older minorities and women

Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis